miércoles, 7 de octubre de 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 19, 2026

Why Billionaire Investor Druckenmiller Sees Stablecoins Dominating Payments In The Next 10 To 15 Years

View original at finance.yahoo.com

Why Billionaire Investor Druckenmiller Sees Stablecoins Dominating Payments In The Next 10 To 15 Years Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

Bitcoin was purchased as a high-beta gold play
60% confidence
Blockchain and stablecoins are incredibly useful in terms of productivity
60% confidence
Cryptocurrency is a solution looking for a problem
60% confidence
Bought Bitcoin in 2020 as a high-beta gold play
60% confidence
Some crypto thing could replace the U.S. dollar as the global reserve currency
60% confidence
No longer held Bitcoin in 2022 due to quantitative tightening by central banks
60% confidence
Some cryptocurrency could replace the U.S. dollar as global reserve currency
60% confidence
Blockchain and stablecoins are incredibly useful for productivity
60% confidence
Crypto has gained traction and will be a store of value
60% confidence
Cryptocurrency will be a store of value due to gained traction
60% confidence
Payment systems will be dominated by stablecoins in 10 to 15 years
60% confidence
No longer holds Bitcoin as of 2022 due to quantitative tightening
60% confidence
Crypto is a solution looking for a problem
60% confidence
Global payment systems will be stablecoins in 10 to 15 years
60% confidence

Lo que sabemos · la inteligencia detrás de esta página

En vivo desde el sustrato

Lo que estamos viendo

Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs

Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.

Nuestra lectura de los datos ›

Señales que seguimos

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patrones que observamos ›

Donde las fuentes discrepan

ING Group

Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.

Señalamos los conflictos abiertamente ›

Verificado recientemente

✓ Verificado con la fuente original

4,986

hechos rastreados a su fuente — y señalamos los que no se sostienen.

101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados

Consulta estos datos → isubstrate.com

Why Billionaire Investor Druckenmiller Sees Stablecoins Dominating Payments In The Next 10 To 15 Years — Source | Via News | es.VIA.NEWS